While the study offers crucial insights into the relationships among PTEN expression, KRAS mutation, and downstream pathways in CRC, it has some limitations: The findings rely on a specific sample set, potentially not fully capturing CRC heterogeneity, other gene mutations, and interactions with other key factors. This evidence concerns the gene KRAS and colorectal carcinoma.